EstroGenomic Profile®

EstroGenomic Profile®

The EstroGenomic® Profile uses genomic testing to identify susceptibility to diseases and conditions such as breast cancer, osteoporosis, and heart disease. More specifically, the EstroGenomic® Profile evaluates genetic variations, called single nucleotide polymorphisms (SNPs) in genes that modulate estrogen metabolism, coagulation, cardiovascular function, bone health, and inflammation.

The EstroGenomic® test uncovers potential genetic susceptibility to diseases and conditions such as:
Breast cancer
Osteoporosis
Thrombosis
Strokes
Atherosclerosis
Heart Disease

Specialized genomic testing from Genova Diagnostics can provide a glimpse into ones potential health future.
Genetic testing enables one to minimize the risk by:
Identifying hidden gene mutations that may promote chronic disease
Preventing disease through early intervention
Modifying gene expression through more precise, targeted, individualized interventions
Identifying key areas for follow-up testing
Monitoring therapeutic effectiveness of intervention strategies with laboratory testing

Whether or not you choose to see genes, they are always there and will continue to play an important role in one´s health. With genomic testing, by choosing to look at them, you have the opportunity to influence the ultimate outcome and more actively promote a healthy life. The EstroGenomic® Profile evaluations include:

Estrogen Metabolism
CYP1A1
GST (M1 and P1)
CYP1B1
COMT (catechol-O-methyl transferase)

Estrogen metabolism SNPs focus on the Phase 1 enzymes involved in the formation of anti- or procarcinogenic metabolites such as 2-hydroxyestrone and 4-hydroxyestrone, respectively, as well as the Phase 2 enzymes responsible for the subsequent metabolism of these compounds. Levels of the various estrogen metabolites modulate risk of both breast cancer and osteoporosis.

HyperCoagulation
GP3a (Glycoprotein 3)
Factor 2 (Prothrombin)
PAI-1 (Plasminogen activator inhibitor-1)
Factor 5 (Leiden)

These genetic variants focus on estrogens interaction with some of the key constituents of the clot formation and fibrinolysis process, such as clotting factors and inhibitors of fibrinolysis. The SNPs can over-activate blood clotting processes, increasing the risk of sudden cardiac events such as thrombosis, heart attacks, and strokes, especially among women take supplemental estrogens and oral contraceptives.

Cardiovascular
Apo E (apoliprotein E)
TNF-a
MTHFR
IL-6

These genes affect how the body processes cholesterol, responds to inflammation, and metabolizes B vitamins. The presence of these SNPs can increase risk of cardiovascular disease, hyperlipidemia, and blood vessel damage.

Osteoporosis
VDR
TNF-a
IL-6
Osteoporosis SNPs relate to estrogens influence on inflammation, bone resorption, vitamin D function and bone collagen formation.

Test Type: Saliva Test